EUVIMEDEUVIMED entdecken
Crossref

IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation

Chunsheng Tsao, Yongchen Ma, Feng Wang, Hang Yu iD, Yunlong Cai, Xudong Zhao, Taohua Yue, Long Rong iD

Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1516-1529

DOI: 10.1111/jgh.70331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 12.03.2026. Verfasst von Chunsheng Tsao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endoscopy Center, Peking University First Hospital, Peking, China. Hauptthemen laut MEDLINE: Oxaliplatin, Stomach Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Beijing Municipal Natural Science Foundation, Foundation for Innovative Research Groups of the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) has poor prognosis and high chemoresistance. This study investigates IKZF3's role in GC progression, oxaliplatin resistance, and underlying mechanisms. IKZF3 expression in GC tissues/cells was assessed using TCGA, qPCR, Western blot, and immunohistochemistry. Prognostic significance was evaluated via Kaplan–Meier analysis. Lentiviral knockdown/overexpression of IKZF3 in HGC27 and AGS cells examined its effects on proliferation, invasion, migration, EMT,tumor stemness and oxaliplatin sensitivity in vitro and in vivo. Additionally, assess whether Iberdomide (an IKZF3 inhibitor) enhances chemosensitivity to oxaliplatin in GC cells in vivo. RNA sequencing (RNA‐seq) identified potential mechanisms. PI3K/AKT/mTOR pathway involvement was tested using PI3K inhibitor LY294002 in rescue experiments. IKZF3 was overexpressed in GC (TCGA/tissue microarrays) and correlated with poor prognosis. Knockdown suppressed proliferation, invasion, migration, EMT, tumor stemness and oxaliplatin resistance in HGC27 cells, while overexpression enhanced these in AGS/HGC27 cells. In vivo, IKZF3 knockdown or inhibitor Iberdomide reduced oxaliplatin resistance. RNA‐seq indicates that IKZF3 knockdown suppressed PI3K/AKT/mTOR pathway activity in HGC27 cells, while overexpression activated it in AGS cells. LY294002 reversed all oncogenic phenotypes and pathway changes induced by IKZF3 modulation. IKZF3 drives GC progression and oxaliplatin resistance by activating PI3K/AKT/mTOR signaling. It is a potential prognostic biomarker and therapeutic target, supporting further development of LY294002 and Iberdomide for GC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinStomach NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktDrug Resistance, NeoplasmPhosphatidylinositol 3-KinasesSignal TransductionIkaros Transcription FactorAntineoplastic AgentsHumansDisease ProgressionAnimalsCell ProliferationCell Line, TumorCell MovementNeoplasm InvasivenessMorpholinesChromones

Stichwörter der Autor:innen

IKZF3LY294002gastric canceriberdomideoxaliplatin

Substanzen

OxaliplatinTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesIkaros Transcription FactorMTOR protein, humanAntineoplastic Agents2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneMorpholinesChromones

Autor:innen und Institutionen

  • Department of Endoscopy Center, Peking University First Hospital, Peking, China.

ORCID-Profile: Hang Yu, Long Rong

Förderung

  • Beijing Municipal Natural Science Foundation
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Tsao, C., Ma, Y., Wang, F., Yu, H., Cai, Y., Zhao, X., Yue, T., & Rong, L. (2026). IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. Journal of Gastroenterology and Hepatology, 41(5), 1516-1529. https://doi.org/10.1111/jgh.70331

Vancouver

Tsao C, Ma Y, Wang F, Yu H, Cai Y, Zhao X, et al. IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. Journal of Gastroenterology and Hepatology. 2026;41(5):1516-1529. doi:10.1111/jgh.70331

BibTeX
@article{Tsao2026,
  author = {Tsao, Chunsheng and Ma, Yongchen and Wang, Feng and Yu, Hang and Cai, Yunlong and Zhao, Xudong and Yue, Taohua and Rong, Long},
  title = {IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {1516--1529},
  doi = {10.1111/jgh.70331}
}
Kostenlos starten →